Target intelligence / Profile preview

Early endosome antigen 1 (EEA1)

Target
EEA1
Molecular classification
Other (endosomal tethering protein, Rab5 effector protein, zinc finger FYVE domain protein, peripheral membrane protein)
01

Overview

Early endosome antigen 1 (EEA1) is a large, alpha-helical, peripheral membrane protein found primarily on the cytoplasmic face of early endosomes in human cells. It is encoded by the EEA1 gene and comprised of 1,411 amino acids. EEA1 binds directly to phosphatidylinositol 3-phosphate in endosomal membranes via its C-terminal FYVE zinc finger domain, and it dimerizes via a coiled-coil region. As a Rab5 effector, EEA1 plays a critical role in mediating the tethering and docking of endocytic vesicles prior to their fusion with early endosomes, thereby regulating endosomal trafficking and cargo sorting. It is essential for proper endocytosis and is recruited to endosomal membranes by Rab5-GTP. EEA1 function may be regulated by post-translational modifications such as monoubiquitination. Dysfunction or manipulation of EEA1 is associated with the ability of certain intracellular pathogens (e.g., Mycobacterium tuberculosis, Legionella species) to evade degradation by interfering with endosomal trafficking[1][2][3][6].

Other names
Endosome-associated protein p162ZFYVE2Zinc finger FYVE domain-containing protein 2
02

Biological functions

Endosomal traffickingVesicle tethering/dockingEndocytosisPhosphatidylinositol 3-phosphate bindingFusion of early endosomesSorting at early endosome
03

Disease associations

Infection (intracellular bacteria modulation)Potential involvement in pathogen entry or avoidance of cellular degradation

Beyond the preview

Go deeper on Early endosome antigen 1 (EEA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Early endosome antigen 1 (EEA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call